View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBBS-Bioactive Bone Substitutes Oyj 将来の成長Future 基準チェック /06BBS-Bioactive Bone Substitutes Oyjは、25.7%と115.8%でそれぞれ年率25.7%で利益と収益が成長すると予測される一方、EPSはgrowで33.4%年率。主要情報25.7%収益成長率33.44%EPS成長率Biotechs 収益成長22.3%収益成長率115.8%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日13 Feb 2025今後の成長に関する最新情報Price Target Changed • Feb 14Price target decreased by 73% to €0.08Down from €0.30, the current price target is provided by 1 analyst. New target price is 49% above last closing price of €0.054. Stock is down 91% over the past year. The company is forecast to post a net loss per share of €0.14 next year compared to a net loss per share of €0.29 last year.すべての更新を表示Recent updatesNew Risk • Feb 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (37% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€1.35m market cap, or US$1.41m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€1.9m net loss in 3 years).Price Target Changed • Feb 14Price target decreased by 73% to €0.08Down from €0.30, the current price target is provided by 1 analyst. New target price is 49% above last closing price of €0.054. Stock is down 91% over the past year. The company is forecast to post a net loss per share of €0.14 next year compared to a net loss per share of €0.29 last year.お知らせ • Feb 06+ 1 more updateBBS-Bioactive Bone Substitutes Announces Resignation of Annastiina Kauppinen as Financial Manager, Effective March 7, 2025BBS-Bioactive Bone Substitutes Oyj announced that Financial manager, Annastiina Kauppinen has decided to resign from BBS. Kauppinen will continue in her position until March 7, 2025.お知らせ • Dec 13+ 1 more updateBBS-Bioactive Bone Substitutes Oyj to Report First Half, 2025 Final Results on Aug 29, 2025BBS-Bioactive Bone Substitutes Oyj announced that they will report first half, 2025 final results on Aug 29, 2025お知らせ • Nov 29Bbs-Bioactive Bone Substitutes plc Announces Resignation of Production Director Kimmo Tyni from the CompanyBBS -Bioactive Bone Substitutes Plc announced that Production Director and the member of management team Kimmo Tyni has decided to resign from BBS and move to a new position outside the Company. Tyni will continue in his position until December 31, 2024.お知らせ • Aug 09BBS-Bioactive Bone Substitutes Oyj to Report Fiscal Year 2024 Results on Feb 21, 2025BBS-Bioactive Bone Substitutes Oyj announced that they will report fiscal year 2024 results on Feb 21, 2025お知らせ • Jun 06BBS-Bioactive Bone Substitutes Plc Announces Approval of Complementary Patent Application for the ARTEBONE® ProductBBS-Bioactive Bone Substitutes Plc's complementary patent application for “A METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION” have been approved in the United States. These claims are related to ARTEBONE®-product and its use in the treatment method. The Company will notify the US patent office that it approves the decision. The patent office will grant the patent after the approval of the Company.お知らせ • May 24BBS-Bioactive Bone Substitutes Plc Announces Ahti Paananen Not Available for Re-Election to the Board of DirectorsBBS-Bioactive Bone Substitutes Plc announced that Ahti Paananen has informed that he is not available for re-election to the board of directors at its Annual General Meeting to be held on 13 June 2024.お知らせ • Apr 03BBS-Bioactive Bone Substitutes Oyj, Annual General Meeting, May 14, 2024BBS-Bioactive Bone Substitutes Oyj, Annual General Meeting, May 14, 2024.お知らせ • Mar 06+ 1 more updateBbs-Bioactive Bone Substitutes Oyj Announces the Cessation of Jari Kortesluoma as Member of the Management TeamOy Jamerco Ltd. has terminated its service contract with BBS-Bioactive Bone Substitutes Oyj. As a result, Jari Kortesluoma’s position as the CFO and member of the management team will end. Kortesluoma will fulfill the responsibilities of CFO throughout the two-month notice period. The company is currently in the process of searching for a new in-house CFO. The appointment will be announced separately.お知らせ • Jan 02Bbs-Bioactive Bone Substitutes plc Appoints Kimmo Tyni as Product Director, effective January 15, 2024BBS-Bioactive Bone Substitutes Plc has appointed Kimmo Tyni (B. Sc. Tech.) as Product Director as of 15.1.2024. The current Product Director Jussi Jukka will transfer from company’s service, to outside of BBS. Tyni will work as a member of the management team of BBS and report to the CEO. Tyni has previous experience in manufacturing processes of medical devices and the standards governing them. He has also worked in companies similar to BBS, where a company is transitioning from a product development to commercial manufacturing.お知らせ • Dec 28+ 2 more updatesBBS-Bioactive Bone Substitutes Oyj, Annual General Meeting, Apr 30, 2024BBS-Bioactive Bone Substitutes Oyj, Annual General Meeting, Apr 30, 2024.お知らせ • Nov 22BBS-Bioactive Bone Substitutes Oyj has filed a Follow-on Equity Offering in the amount of €2.631392 million.BBS-Bioactive Bone Substitutes Oyj has filed a Follow-on Equity Offering in the amount of €2.631392 million. Security Name: Shares Security Type: Common Stock Securities Offered: 6,578,481 Price\Range: €0.4 Transaction Features: Rights Offeringお知らせ • Oct 05BBS-Bioactive Bone Substitutes Plc Announces CEO ChangesBBS-Bioactive Bone Substitutes Plc announced a strategic leadership transition, appointing Juliusz Rakowskias the new Chief Executive Officer (CEO), effective 3 November 2023. The Company and the current CEO Ilkka Kangasniemi have mutually agreed that he will continue to offer his insights and expertise to the company in an advisory capacity. The appointment signifies the company's on-going transition from research and development to a commercial phase, as the approval of the CE marking of the Company's first product (ARTEBONE® Paste) is expected during Q2/2024. Juliusz Rakowski brings a strong track record of leadership and a deep understanding of product sales processes in the life science industry to BBS. With over 15 years of commercial experience in relevant industry roles, he is poised to lead BBS into its next phase of product launch, building the distribution network and market expansion.お知らせ • Aug 26BBS-Bioactive Bone Substitutes Oyj to Report Fiscal Year 2023 Results on Feb 22, 2024BBS-Bioactive Bone Substitutes Oyj announced that they will report fiscal year 2023 results on Feb 22, 2024お知らせ • Feb 14BBS-Bioactive Bone Substitutes Applies for the Delisting of Secondary Listing on Nasdaq First North Growth Market SwedenBBS-Bioactive Bone Substitutes Oyj announced that following the earlier announcement made on 4 November 2022, the company has on February 13, 2023 applied for the delisting of its shares from Nasdaq First North Growth Market Sweden (‘Nasdaq FN GM Sweden’). The Board of directors has taken into account the low level of trading activity of the Company's shares since its listing on the Exchange in 2018, as well as the limited number of shareholders registered with Euroclear Sweden AB. The Board has also evaluated the additional expenses associated with maintaining a secondary listing for a company of its size and the administrative responsibilities entailed by complying with the listing requirements of multiple markets. The Company wants to remind its shareholders holding their shares through Euroclear Sweden AB that even while the listing of its shares on Nasdaq FN GM Sweden will be discontinued, such shareholders can continue trading in BBS’ shares on Nasdaq First North Growth Market Finland by first arranging for the cross-border settlement of their shares into the book-entry system maintained by Euroclear Finland Oy. To effectuate cross-border settlement, the shareholder should contact their respective custodian. Some custodians will automatically do the settlement, and others will activate the cross-border settlement after approval by the shareholder. The Company expects the final day of trading on Nasdaq First North Growth Market Sweden to occur on 6 March 2023. The company will provide additional details regarding the delisting following a decision from Nasdaq Sweden on the application. Following the delisting from Sweden, BBS-Bioactive Bone Substitutes’s shares will be traded solely on Nasdaq First North Growth Market Finland in Euro and under the trading code: BONEH.お知らせ • Dec 15+ 2 more updatesBBS-Bioactive Bone Substitutes Oyj, Annual General Meeting, Apr 28, 2023BBS-Bioactive Bone Substitutes Oyj, Annual General Meeting, Apr 28, 2023.お知らせ • Nov 05BBS-Bioactive Bone Substitutes Announces Plans to Withdraw Its Dual Listing on Nasdaq First North Growth Market SwedenBBS-Bioactive Bone Substitutes Oyj's (”BBS”) Board of Directors has decided on November 4, 2022, that the company will initiate preparations to withdraw its dual listing on Nasdaq First North Growth Market Sweden (the "First North Sweden"), as it focuses on the listing on Nasdaq First North Growth Market Finland ("First North Finland"). The formal withdrawal application will be submitted to Nasdaq no earlier than three months from November 4, 2022. The reason for the withdrawal is the low trading volume on the First North Sweden. Therefore, the Board aims to concentrate all trading on a single market, First North Finland, to increase trading and thereby give the shareholders better opportunities to buy and sell shares in the company.お知らせ • Oct 08+ 1 more updateBbs-Bioactive Bone Substitutes Oyj Announces Appointment of Jari Kortesluoma as CFOJari Kortesluoma has been appointed as CFO and member of the management team of BBS-Bioactive Bone Substitutes Plc as of 7 October 2022. Since 2006, Kortesluoma has worked as a consultant and entrepreneur offering financial management services. Previously, he has acted as the CFO of the medical device manufacturer Ozics Group (2009-2017), as the CFO of Inion Ltd. (2003-2006) and as the CFO of Flextronics International (1997-2002). In addition, he has worked in financial management and controller roles in several other international companies. As previously announced on 31 August 2022, the company’s previous CFO Liisa Hukka has left the company to take on new challenges outside the company as of the end of September.分析記事 • Sep 16We Think BBS-Bioactive Bone Substitutes Oyj (HEL:BONEH) Has A Fair Chunk Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...お知らせ • Sep 01BBS-Bioactive Bone Substitutes Oyj Announces Resignation of Liisa Hukka, CFOBBS-Bioactive Bone Substitutes Oyj's CFO and member of the management team, Liisa Hukka, has announced that she is leaving the company to take on new challenges outside the company. She will stop her work during September 2022.お知らせ • Aug 08Bbs-Bioactive Bone Substitutes Oyj Announces Changes in the Management TeamBBS-Bioactive Bone Substitutes Plc's (BBS) Chief Operating Officer (COO) and member of the Management Team, Hanna Tölli, will take a personal leave from August 8, 2022 to October 23, 2023. Jussi Jukka, who currently works as a production manager at BBS, has been appointed the new Head of Production and member of the Management Team as of August 8, 2022.Board Change • May 04Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Seppo Nevalainen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 02BBS-Bioactive Bone Substitutes Plc Elects Ahti Paananen as A New MemberBBS-Bioactive Bone Substitutes Plc announced that at its Annual General Meeting 2022 held on April 28th 2022, Ahti Paananen was elected as a new member.お知らせ • Jan 12BBS-Bioactive Bone Substitutes Oyj Announces US Patent for the Manufacture of Artebone ProductBBS-Bioactive Bone Substitutes Plc announced US Patent for the Manufacture of ARTEBONE® product, As announced in November 17 2021 release “A METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION”, after the approval of the patent application for manufacturing claims of BBS-Bioactive Bone Substitutes Plc's, this patent has now been granted in the United States on January 11, 2022.分析記事 • Dec 20BBS-Bioactive Bone Substitutes Oyj (HEL:BONEH) Is Making Moderate Use Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Sep 02BBS-Bioactive Bone Substitutes Oyj (HEL:BONEH) Is Making Moderate Use Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Apr 27BBS-Bioactive Bone Substitutes Oyj Announces Submission of CE Marking Application for Artebone® Products Moves to AugustThe management of BBS-Bioactive Bone Substitutes Plc has changed its estimate regarding the submission date of the ARTEBONE® products CE marking application. The company expects to submit the application during August this year. Earlier, the company had estimated that the application could be submitted during April this year. The delay is due to equipment, material and service deliveries to Oulu laboratory and Reisjärvi factory being delayed significantly due to the COVID-19 situation. Repairing a detected structural fault in Reisjärvi factory’s clean room has delayed the start of the validation process. In addition, the results from the animal testing have been delayed significantly. The delays are causing similar delays to the forecast CE marking approval schedule. Notified Bodies’ application processing times have been prolonged due to MDR regulation. It is still unclear to what extent prolongation of processing times may result in a delay in the CE marking approval process.分析記事 • Feb 27Is BBS-Bioactive Bone Substitutes Oyj (HEL:BONEH) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Is New 90 Day High Low • Feb 26New 90-day low: €3.52The company is down 28% from its price of €4.90 on 27 November 2020. The Finnish market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period.Executive Departure • Feb 04Chief Financial Officer has left the companyOn the 1st of February, Hannu Säynäjäkangas' tenure in the role of Chief Financial Officer ended. We don't have any record of a personal shareholding under Hannu's name. A total of 2 executives have left over the last 12 months.お知らせ • Feb 02BBS-Bioactive Bone Substitutes plc Announces Executive ChangesBBS-Bioactive Bone Substitutes Oyj announced that Liisa Hukka from Talenom Plc. has been appointed chief financial officer (CFO) of the company. Hukka will take up her position on 1 February, 2021, when the Company’s current CFO Hannu Säynäjäkangasretires. Hukka works on BBS’ Management Team and reports to the CEO. For the past 5 years, Hukka has worked as a financial administration consultant at Talenom. Prior to that, she worked as CFO at Nestor Cable and in various financial management and business support positions at the Dutch Draka Holding BV Group.Is New 90 Day High Low • Jan 26New 90-day low: €3.88The company is down 6.0% from its price of €4.14 on 27 October 2020. The Finnish market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period.お知らせ • Jan 12BBS-Bioactive Bone Substitutes plc Estimates That the Company Will Receive the CE Marking for the Artebone® Product Designed to Heal Bone Fractures and Damages During 2021BBS-Bioactive Bone Substitutes Plc estimated that the Company will receive the CE marking for the ARTEBONE® product designed to heal bone fractures and damages during 2021. The obtaining of the CE marking will be delayed from the previous schedule about 9 months and will cause the additional expenses of approximately EUR 300.000. The Company intends to submit the application for processing in approximately April. In July 2020 BBS received the draft agreement concerning the implementation of CE marking process of ARTEBONE® from Notified Body (BSI). The Company began preparations to submit CE marking application and documents required by the agreement processing as soon as possible. At a general level, the Covid-19 pandemic has caused delays and made the operating environment more difficult. During autumn, the ongoing commissioning of new Medical Device Regulation (MDR) in Europe has highlighted significant number of unfinished documents, quality tests and qualifications of production equipment in the Company. In addition, the Notified Body demands that all documents must be ready for submission at the same time with the CE marking application, whereas according to previous practice, the application could be supplemented during the application process. Furthermore, the further measurements of the animal experiment required by the authority have had to wait longer than expected (The company announcement 7 August 2020). The Company has initiated efforts to remedy the situation. The Company has entered into purchasing service agreements with third parties to speed up the production and updating of the necessary documents. In addition, three people have been hired to support the activities of the quality department so far. At a later stage, these individuals move to other positions within the Company. The product approval schedule has naturally changed. The Company’s current management has assessed a new timetable for obtaining the CE marking. Currently, the Company intends to submit the application for processing in approximately April 2021. Thus, the approval of the CE marking is expected to be completed by the end of 2021, approximately 9 months later than the previously estimated schedule. The Board's assessment of the factors affecting the timing of the approval process is that the ongoing significant reform of the regulatory process guidelines has caused major changes to the level of documentation requirements. A new quality director was hired for the Company in August, who has begun vigorously supplementing the necessary documents. According to the CEO's estimate, the additional expenses of the changes will be approximately EUR 300.000. The current management of the Company has formed a new schedule estimate after learning of all the shortcomings.お知らせ • Dec 23+ 2 more updatesBBS-Bioactive Bone Substitutes Oyj to Report First Half, 2021 Results on Aug 25, 2021BBS-Bioactive Bone Substitutes Oyj announced that they will report first half, 2021 results on Aug 25, 2021お知らせ • Nov 10BBS-Bioactive Bone Substitutes Plc Announces Whole Patent Regarding the Product ARTEBONE® Has Been Accepted in the USABBS-Bioactive Bone Substitutes Plc’s patent application ”A METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION” has now been accepted in the USA. Earlier in spring (7.4.2020) the company announced the acceptance of the same patent concerning the product. Now the ARTEBONE® product and its unique component, bone protein extract, are protected by patents around all major market areas globally.Is New 90 Day High Low • Nov 06New 90-day low: €3.96The company is down 7.0% from its price of €4.26 on 07 August 2020. The Finnish market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period.お知らせ • Sep 01BBS-Bioactive Bone Substitutes Oyj to Report Fiscal Year 2020 Results on Mar 20, 2021BBS-Bioactive Bone Substitutes Oyj announced that they will report fiscal year 2020 results on Mar 20, 2021業績と収益の成長予測HLSE:BONEH - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20271-100112/31/2026N/A-3-2-2112/31/2025N/A-3-2-2112/31/2024N/A-3-2-316/30/2024N/A-4-3-3N/A3/31/2024N/A-4-3-3N/A12/31/2023N/A-3-3-3N/A3/31/2023N/A-3-3-3N/A12/31/2022N/A-3-3-3N/A9/30/2022N/A-3-3-3N/A6/30/2022N/A-3-3-3N/A3/31/2022N/A-3-3-3N/A12/31/2021N/A-3-3-3N/A9/30/2021N/A-3-3-3N/A6/30/2021N/A-3-3-3N/A3/31/2021N/A-3-3-3N/A12/31/2020N/A-3-2-2N/A9/30/2020N/A-2-2-2N/A6/30/2020N/A-2-2-2N/A3/31/2020N/A-2-2-2N/A12/31/2019N/A-2-1-1N/A9/30/2019N/A-2-1-1N/A6/30/2019N/A-2-1-1N/A3/31/2019N/A-1-2-2N/A12/31/2018N/A0-2-2N/A9/30/2018N/A-1-2-2N/A6/30/2018N/A-3-2-2N/A3/31/2018N/A-4N/A-1N/A12/31/2017N/A-4N/A-1N/A12/31/2016N/A-1N/A-1N/A12/31/2015N/A-1N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BONEH今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: BONEH今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: BONEH今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: BONEH来年は収益がないと予測されています。高い収益成長: BONEH来年は収益がないと予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BONEHの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/03/04 10:41終値2025/02/12 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BBS-Bioactive Bone Substitutes Oyj 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Marianne PalmuInderes OyAntti SiltanenInderes Oy
Price Target Changed • Feb 14Price target decreased by 73% to €0.08Down from €0.30, the current price target is provided by 1 analyst. New target price is 49% above last closing price of €0.054. Stock is down 91% over the past year. The company is forecast to post a net loss per share of €0.14 next year compared to a net loss per share of €0.29 last year.
New Risk • Feb 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (37% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (€1.35m market cap, or US$1.41m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€1.9m net loss in 3 years).
Price Target Changed • Feb 14Price target decreased by 73% to €0.08Down from €0.30, the current price target is provided by 1 analyst. New target price is 49% above last closing price of €0.054. Stock is down 91% over the past year. The company is forecast to post a net loss per share of €0.14 next year compared to a net loss per share of €0.29 last year.
お知らせ • Feb 06+ 1 more updateBBS-Bioactive Bone Substitutes Announces Resignation of Annastiina Kauppinen as Financial Manager, Effective March 7, 2025BBS-Bioactive Bone Substitutes Oyj announced that Financial manager, Annastiina Kauppinen has decided to resign from BBS. Kauppinen will continue in her position until March 7, 2025.
お知らせ • Dec 13+ 1 more updateBBS-Bioactive Bone Substitutes Oyj to Report First Half, 2025 Final Results on Aug 29, 2025BBS-Bioactive Bone Substitutes Oyj announced that they will report first half, 2025 final results on Aug 29, 2025
お知らせ • Nov 29Bbs-Bioactive Bone Substitutes plc Announces Resignation of Production Director Kimmo Tyni from the CompanyBBS -Bioactive Bone Substitutes Plc announced that Production Director and the member of management team Kimmo Tyni has decided to resign from BBS and move to a new position outside the Company. Tyni will continue in his position until December 31, 2024.
お知らせ • Aug 09BBS-Bioactive Bone Substitutes Oyj to Report Fiscal Year 2024 Results on Feb 21, 2025BBS-Bioactive Bone Substitutes Oyj announced that they will report fiscal year 2024 results on Feb 21, 2025
お知らせ • Jun 06BBS-Bioactive Bone Substitutes Plc Announces Approval of Complementary Patent Application for the ARTEBONE® ProductBBS-Bioactive Bone Substitutes Plc's complementary patent application for “A METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION” have been approved in the United States. These claims are related to ARTEBONE®-product and its use in the treatment method. The Company will notify the US patent office that it approves the decision. The patent office will grant the patent after the approval of the Company.
お知らせ • May 24BBS-Bioactive Bone Substitutes Plc Announces Ahti Paananen Not Available for Re-Election to the Board of DirectorsBBS-Bioactive Bone Substitutes Plc announced that Ahti Paananen has informed that he is not available for re-election to the board of directors at its Annual General Meeting to be held on 13 June 2024.
お知らせ • Apr 03BBS-Bioactive Bone Substitutes Oyj, Annual General Meeting, May 14, 2024BBS-Bioactive Bone Substitutes Oyj, Annual General Meeting, May 14, 2024.
お知らせ • Mar 06+ 1 more updateBbs-Bioactive Bone Substitutes Oyj Announces the Cessation of Jari Kortesluoma as Member of the Management TeamOy Jamerco Ltd. has terminated its service contract with BBS-Bioactive Bone Substitutes Oyj. As a result, Jari Kortesluoma’s position as the CFO and member of the management team will end. Kortesluoma will fulfill the responsibilities of CFO throughout the two-month notice period. The company is currently in the process of searching for a new in-house CFO. The appointment will be announced separately.
お知らせ • Jan 02Bbs-Bioactive Bone Substitutes plc Appoints Kimmo Tyni as Product Director, effective January 15, 2024BBS-Bioactive Bone Substitutes Plc has appointed Kimmo Tyni (B. Sc. Tech.) as Product Director as of 15.1.2024. The current Product Director Jussi Jukka will transfer from company’s service, to outside of BBS. Tyni will work as a member of the management team of BBS and report to the CEO. Tyni has previous experience in manufacturing processes of medical devices and the standards governing them. He has also worked in companies similar to BBS, where a company is transitioning from a product development to commercial manufacturing.
お知らせ • Dec 28+ 2 more updatesBBS-Bioactive Bone Substitutes Oyj, Annual General Meeting, Apr 30, 2024BBS-Bioactive Bone Substitutes Oyj, Annual General Meeting, Apr 30, 2024.
お知らせ • Nov 22BBS-Bioactive Bone Substitutes Oyj has filed a Follow-on Equity Offering in the amount of €2.631392 million.BBS-Bioactive Bone Substitutes Oyj has filed a Follow-on Equity Offering in the amount of €2.631392 million. Security Name: Shares Security Type: Common Stock Securities Offered: 6,578,481 Price\Range: €0.4 Transaction Features: Rights Offering
お知らせ • Oct 05BBS-Bioactive Bone Substitutes Plc Announces CEO ChangesBBS-Bioactive Bone Substitutes Plc announced a strategic leadership transition, appointing Juliusz Rakowskias the new Chief Executive Officer (CEO), effective 3 November 2023. The Company and the current CEO Ilkka Kangasniemi have mutually agreed that he will continue to offer his insights and expertise to the company in an advisory capacity. The appointment signifies the company's on-going transition from research and development to a commercial phase, as the approval of the CE marking of the Company's first product (ARTEBONE® Paste) is expected during Q2/2024. Juliusz Rakowski brings a strong track record of leadership and a deep understanding of product sales processes in the life science industry to BBS. With over 15 years of commercial experience in relevant industry roles, he is poised to lead BBS into its next phase of product launch, building the distribution network and market expansion.
お知らせ • Aug 26BBS-Bioactive Bone Substitutes Oyj to Report Fiscal Year 2023 Results on Feb 22, 2024BBS-Bioactive Bone Substitutes Oyj announced that they will report fiscal year 2023 results on Feb 22, 2024
お知らせ • Feb 14BBS-Bioactive Bone Substitutes Applies for the Delisting of Secondary Listing on Nasdaq First North Growth Market SwedenBBS-Bioactive Bone Substitutes Oyj announced that following the earlier announcement made on 4 November 2022, the company has on February 13, 2023 applied for the delisting of its shares from Nasdaq First North Growth Market Sweden (‘Nasdaq FN GM Sweden’). The Board of directors has taken into account the low level of trading activity of the Company's shares since its listing on the Exchange in 2018, as well as the limited number of shareholders registered with Euroclear Sweden AB. The Board has also evaluated the additional expenses associated with maintaining a secondary listing for a company of its size and the administrative responsibilities entailed by complying with the listing requirements of multiple markets. The Company wants to remind its shareholders holding their shares through Euroclear Sweden AB that even while the listing of its shares on Nasdaq FN GM Sweden will be discontinued, such shareholders can continue trading in BBS’ shares on Nasdaq First North Growth Market Finland by first arranging for the cross-border settlement of their shares into the book-entry system maintained by Euroclear Finland Oy. To effectuate cross-border settlement, the shareholder should contact their respective custodian. Some custodians will automatically do the settlement, and others will activate the cross-border settlement after approval by the shareholder. The Company expects the final day of trading on Nasdaq First North Growth Market Sweden to occur on 6 March 2023. The company will provide additional details regarding the delisting following a decision from Nasdaq Sweden on the application. Following the delisting from Sweden, BBS-Bioactive Bone Substitutes’s shares will be traded solely on Nasdaq First North Growth Market Finland in Euro and under the trading code: BONEH.
お知らせ • Dec 15+ 2 more updatesBBS-Bioactive Bone Substitutes Oyj, Annual General Meeting, Apr 28, 2023BBS-Bioactive Bone Substitutes Oyj, Annual General Meeting, Apr 28, 2023.
お知らせ • Nov 05BBS-Bioactive Bone Substitutes Announces Plans to Withdraw Its Dual Listing on Nasdaq First North Growth Market SwedenBBS-Bioactive Bone Substitutes Oyj's (”BBS”) Board of Directors has decided on November 4, 2022, that the company will initiate preparations to withdraw its dual listing on Nasdaq First North Growth Market Sweden (the "First North Sweden"), as it focuses on the listing on Nasdaq First North Growth Market Finland ("First North Finland"). The formal withdrawal application will be submitted to Nasdaq no earlier than three months from November 4, 2022. The reason for the withdrawal is the low trading volume on the First North Sweden. Therefore, the Board aims to concentrate all trading on a single market, First North Finland, to increase trading and thereby give the shareholders better opportunities to buy and sell shares in the company.
お知らせ • Oct 08+ 1 more updateBbs-Bioactive Bone Substitutes Oyj Announces Appointment of Jari Kortesluoma as CFOJari Kortesluoma has been appointed as CFO and member of the management team of BBS-Bioactive Bone Substitutes Plc as of 7 October 2022. Since 2006, Kortesluoma has worked as a consultant and entrepreneur offering financial management services. Previously, he has acted as the CFO of the medical device manufacturer Ozics Group (2009-2017), as the CFO of Inion Ltd. (2003-2006) and as the CFO of Flextronics International (1997-2002). In addition, he has worked in financial management and controller roles in several other international companies. As previously announced on 31 August 2022, the company’s previous CFO Liisa Hukka has left the company to take on new challenges outside the company as of the end of September.
分析記事 • Sep 16We Think BBS-Bioactive Bone Substitutes Oyj (HEL:BONEH) Has A Fair Chunk Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
お知らせ • Sep 01BBS-Bioactive Bone Substitutes Oyj Announces Resignation of Liisa Hukka, CFOBBS-Bioactive Bone Substitutes Oyj's CFO and member of the management team, Liisa Hukka, has announced that she is leaving the company to take on new challenges outside the company. She will stop her work during September 2022.
お知らせ • Aug 08Bbs-Bioactive Bone Substitutes Oyj Announces Changes in the Management TeamBBS-Bioactive Bone Substitutes Plc's (BBS) Chief Operating Officer (COO) and member of the Management Team, Hanna Tölli, will take a personal leave from August 8, 2022 to October 23, 2023. Jussi Jukka, who currently works as a production manager at BBS, has been appointed the new Head of Production and member of the Management Team as of August 8, 2022.
Board Change • May 04Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Seppo Nevalainen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 02BBS-Bioactive Bone Substitutes Plc Elects Ahti Paananen as A New MemberBBS-Bioactive Bone Substitutes Plc announced that at its Annual General Meeting 2022 held on April 28th 2022, Ahti Paananen was elected as a new member.
お知らせ • Jan 12BBS-Bioactive Bone Substitutes Oyj Announces US Patent for the Manufacture of Artebone ProductBBS-Bioactive Bone Substitutes Plc announced US Patent for the Manufacture of ARTEBONE® product, As announced in November 17 2021 release “A METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION”, after the approval of the patent application for manufacturing claims of BBS-Bioactive Bone Substitutes Plc's, this patent has now been granted in the United States on January 11, 2022.
分析記事 • Dec 20BBS-Bioactive Bone Substitutes Oyj (HEL:BONEH) Is Making Moderate Use Of DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Sep 02BBS-Bioactive Bone Substitutes Oyj (HEL:BONEH) Is Making Moderate Use Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Apr 27BBS-Bioactive Bone Substitutes Oyj Announces Submission of CE Marking Application for Artebone® Products Moves to AugustThe management of BBS-Bioactive Bone Substitutes Plc has changed its estimate regarding the submission date of the ARTEBONE® products CE marking application. The company expects to submit the application during August this year. Earlier, the company had estimated that the application could be submitted during April this year. The delay is due to equipment, material and service deliveries to Oulu laboratory and Reisjärvi factory being delayed significantly due to the COVID-19 situation. Repairing a detected structural fault in Reisjärvi factory’s clean room has delayed the start of the validation process. In addition, the results from the animal testing have been delayed significantly. The delays are causing similar delays to the forecast CE marking approval schedule. Notified Bodies’ application processing times have been prolonged due to MDR regulation. It is still unclear to what extent prolongation of processing times may result in a delay in the CE marking approval process.
分析記事 • Feb 27Is BBS-Bioactive Bone Substitutes Oyj (HEL:BONEH) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Is New 90 Day High Low • Feb 26New 90-day low: €3.52The company is down 28% from its price of €4.90 on 27 November 2020. The Finnish market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period.
Executive Departure • Feb 04Chief Financial Officer has left the companyOn the 1st of February, Hannu Säynäjäkangas' tenure in the role of Chief Financial Officer ended. We don't have any record of a personal shareholding under Hannu's name. A total of 2 executives have left over the last 12 months.
お知らせ • Feb 02BBS-Bioactive Bone Substitutes plc Announces Executive ChangesBBS-Bioactive Bone Substitutes Oyj announced that Liisa Hukka from Talenom Plc. has been appointed chief financial officer (CFO) of the company. Hukka will take up her position on 1 February, 2021, when the Company’s current CFO Hannu Säynäjäkangasretires. Hukka works on BBS’ Management Team and reports to the CEO. For the past 5 years, Hukka has worked as a financial administration consultant at Talenom. Prior to that, she worked as CFO at Nestor Cable and in various financial management and business support positions at the Dutch Draka Holding BV Group.
Is New 90 Day High Low • Jan 26New 90-day low: €3.88The company is down 6.0% from its price of €4.14 on 27 October 2020. The Finnish market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period.
お知らせ • Jan 12BBS-Bioactive Bone Substitutes plc Estimates That the Company Will Receive the CE Marking for the Artebone® Product Designed to Heal Bone Fractures and Damages During 2021BBS-Bioactive Bone Substitutes Plc estimated that the Company will receive the CE marking for the ARTEBONE® product designed to heal bone fractures and damages during 2021. The obtaining of the CE marking will be delayed from the previous schedule about 9 months and will cause the additional expenses of approximately EUR 300.000. The Company intends to submit the application for processing in approximately April. In July 2020 BBS received the draft agreement concerning the implementation of CE marking process of ARTEBONE® from Notified Body (BSI). The Company began preparations to submit CE marking application and documents required by the agreement processing as soon as possible. At a general level, the Covid-19 pandemic has caused delays and made the operating environment more difficult. During autumn, the ongoing commissioning of new Medical Device Regulation (MDR) in Europe has highlighted significant number of unfinished documents, quality tests and qualifications of production equipment in the Company. In addition, the Notified Body demands that all documents must be ready for submission at the same time with the CE marking application, whereas according to previous practice, the application could be supplemented during the application process. Furthermore, the further measurements of the animal experiment required by the authority have had to wait longer than expected (The company announcement 7 August 2020). The Company has initiated efforts to remedy the situation. The Company has entered into purchasing service agreements with third parties to speed up the production and updating of the necessary documents. In addition, three people have been hired to support the activities of the quality department so far. At a later stage, these individuals move to other positions within the Company. The product approval schedule has naturally changed. The Company’s current management has assessed a new timetable for obtaining the CE marking. Currently, the Company intends to submit the application for processing in approximately April 2021. Thus, the approval of the CE marking is expected to be completed by the end of 2021, approximately 9 months later than the previously estimated schedule. The Board's assessment of the factors affecting the timing of the approval process is that the ongoing significant reform of the regulatory process guidelines has caused major changes to the level of documentation requirements. A new quality director was hired for the Company in August, who has begun vigorously supplementing the necessary documents. According to the CEO's estimate, the additional expenses of the changes will be approximately EUR 300.000. The current management of the Company has formed a new schedule estimate after learning of all the shortcomings.
お知らせ • Dec 23+ 2 more updatesBBS-Bioactive Bone Substitutes Oyj to Report First Half, 2021 Results on Aug 25, 2021BBS-Bioactive Bone Substitutes Oyj announced that they will report first half, 2021 results on Aug 25, 2021
お知らせ • Nov 10BBS-Bioactive Bone Substitutes Plc Announces Whole Patent Regarding the Product ARTEBONE® Has Been Accepted in the USABBS-Bioactive Bone Substitutes Plc’s patent application ”A METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION” has now been accepted in the USA. Earlier in spring (7.4.2020) the company announced the acceptance of the same patent concerning the product. Now the ARTEBONE® product and its unique component, bone protein extract, are protected by patents around all major market areas globally.
Is New 90 Day High Low • Nov 06New 90-day low: €3.96The company is down 7.0% from its price of €4.26 on 07 August 2020. The Finnish market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period.
お知らせ • Sep 01BBS-Bioactive Bone Substitutes Oyj to Report Fiscal Year 2020 Results on Mar 20, 2021BBS-Bioactive Bone Substitutes Oyj announced that they will report fiscal year 2020 results on Mar 20, 2021